Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Albany Molecular Research, Inc.    AMRI

News SummaryMost relevantAll newsSector newsTweets 

Albany Molecular Research, Inc. : AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations

share with twitter share with LinkedIn share with facebook
share via e-mail
03/27/2012 | 02:05pm CEST

ALBANY, N.Y., March 27, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today another key addition to its management team at its aseptic fill and finish facility in Burlington, Mass. Stephen Rossmeisl has joined the company as Senior Facilities Manager, reporting to Eric Peterson, Director of Manufacturing. Mr. Rossmeisl's more than 15 years of plant engineering and facilities management experience will provide the expertise and leadership necessary to effectively plan and implement facility maintenance programs, environmental monitoring compliance systems and expansion projects.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Combined with previously announced recent senior leadership changes at Burlington, Mr. Rossmeisl's addition further demonstrates AMRI's commitment to providing industry leading aseptic services with uncompromising quality to the company's growing client base.

AMRI's Burlington, Mass. facility offers clients innovative aseptic formulation and filling services for pre-clinical through small-volume, commercial-scale production of liquid-filled parenterals, biologics and medical devices in vials, syringes and other custom containers.

Mr. Rossmeisl has worked for large pharmaceutical companies performing all phases of construction, design, and commissioning. He comes to AMRI from his most recent role as the Associate Director of Facilities Operations for Shire HGT in Lexington, Mass., where in addition to maintenance oversight he served as the lead project engineer for significant laboratory and office expansion projects. Mr. Rossmeisl's experience with critical cleanroom equipment, utilities and systems will strengthen AMRI's ability to meet the growing needs of its customers as the level of activity of new business at Burlington continues on a path to a return to previously robust levels.

"Steve brings extensive knowledge and experience in supporting critical cleanroom infrastructure, equipment and GMP operations," said Steven R. Hagen, Ph.D., Vice President, Pharmaceutical Development and Manufacturing, AMRI. "Steve will be instrumental in ensuring compliance and overall effectiveness of the facility's preventive maintenance program and critical environmental monitoring systems, and will lead the planning, oversight and execution of future expansion projects."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization with more than twenty years experience providing customers fully integrated drug discovery, development, and manufacturing services. AMRI supplies a broad range of services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of API and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, AMRI maintains geographic proximity and flexible cost models. AMRI has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. AMRI has successfully partnered certain programs and is actively seeking to out-license its remaining programs to strategic partners for further development.


share with twitter share with LinkedIn share with facebook
share via e-mail
05/10 ALBANY MOLECULAR RESEARCH, INC. (NAS : AMRI) Files An 8-K Results of Operations ..
05/10 ALBANY MOLECULAR RESEARCH INC : Results of Operations and Financial Condition, F..
05/10 ALBANY MOLECULAR RESEARCH : Management's Discussion and Analysis of Financial Co..
05/09 ALBANY MOLECULAR RESEARCH, INC. (NAS : AMRI) reported earnings of $0.13 per shar..
05/09 ALBANY MOLECULAR RESEARCH, INC. : Investor Network: Albany Molecular Research, I..
05/09 AMRI : Announces First Quarter 2017 Results
04/24 ALBANY MOLECULAR RESEARCH : Denovo Biopharma Obtains Exclusive License To Liafen..
02/21 ALBANY MOLECULAR RESEARCH INC : Results of Operations and Financial Condition, C..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/11 Premarket analyst action - healthcare
05/09 Albany Molecular Research, Inc. 2017 Q1 - Results - Earnings Call Slides
05/09 Albany Molecular Research's (AMRI) CEO William Marth on Q1 2017 Results - Ear..
05/09 Albany Molecular beats by $0.01, beats on revenue
05/08 Notable earnings before Tuesday?s open